CyGene Laboratories Receives CLIA Laboratory Registration.CORAL SPRINGS, Fla. -- CyGene Laboratories Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :CYGE) ("the Company") announced today that the State of Florida Agency for Health Care Administration has provided the Company with a certificate that will allow its laboratory to receive human specimens for clinical diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease . The certificate was issued under the Federal Clinical Laboratory Improvement Amendments Clinical Laboratory Improvement Amendments (CLIA) of 1988 are United States federal regulatory standards that apply to all clinical laboratory testing performed on humans in the United States, except clinical trials and basic research. (CLIA CLIA Clinical Laboratory Improvement Amendments of 1988 Congressional legislation that promulgated quality assurance practices in clinical labs, and required them to measure performance at each step of the testing process from the beginning to the end-point of a ). Martin Munzer, CyGene's president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , said, "Achieving this milestone significantly enhances our ability to introduce new genetic testing Genetic Testing Definition A genetic test examines the genetic information contained inside a person's cells, called DNA, to determine if that person has or will develop a certain disease or could pass a disease to his or her offspring. products into the medical marketplace. Last year we began to build a sales force; we now have 21 independent medical sales representatives who are introducing our products to medical professionals. CyGene's current line of predictive DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. products is being enhanced with diagnostic genetic tests that will help physicians treat their patients using information from the latest genetic scientific discoveries." Munzer also noted, "Now that our services are eligible for reimbursement, we are confident that healthcare providers will more assertively implement these inexpensive preventative technologies." Dr. Jeffrey Pinco, MD, CyGene's medical director, added, "The new line of diagnostic products is in tune with CyGene's philosophy of offering products with results that are affordable, anonymous and action-oriented, rather than just diagnosing inevitable genetic disorders for which little corrective action can be taken. The bright future of this emerging industry comes from using genetic information in a form that will benefit public health in an unprecedented way. We are proud to be a part of this exciting new field." For more information about CyGene Laboratories and its products and technologies, visit the Company's Web site at www.CyGeneDirect.com. About CyGene Laboratories Inc. CyGene Laboratories Inc., based in Coral Springs, Florida Coral Springs, officially chartered July 10, 1963, is a city in Broward County, Florida, United States, approximately 20 miles (32 km) northwest of Fort Lauderdale, Florida. According to the U.S. , is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. CyGene's scientific base rests on its DNA Haystack Processing technologies, which it has been developing since 1995. CyGene currently markets five predictive DNA tests direct to consumers and through physicians and other healthcare practitioners. Forward-Looking Statements: The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion